A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)
ASCO 2023
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients